Tag: Eli Lilly
-

Eli Lilly’s Jaypirca Wins FDA Approval for First-Line CLL/SLL
The noncovalent BTK inhibitor reduced the risk of progression or death by 80% versus bendamustine plus rituximab in previously untreated patients without known del(17p). Key Takeaways Data Snapshot Item Details Company Eli Lilly Drug Jaypirca (pirtobrutinib) FDA approval date October 2, 2026 Indication Previously untreated adult CLL/SLL without known del(17p) Pivotal trial Phase 3 BRUIN…
-

Eli Lilly to Acquire Merida Biosciences for Up to $2.875 Billion
Eli Lilly will acquire Merida Biosciences for up to $2.875 billion, gaining a precision autoantibody-degradation platform and multiple immunology programs.
-

Eli Lilly Wins FDA Approval for Mounjaro to Reduce Cardiovascular Risk
The FDA approved Mounjaro (tirzepatide) to reduce major cardiovascular events in adults with type 2 diabetes at high cardiovascular risk.
-

Roche and Eli Lilly Win FDA Clearance for Alzheimer’s Blood Test
Roche and Eli Lilly received FDA clearance for Elecsys pTau217, a single-biomarker blood test designed to assess Alzheimer’s-related amyloid pathology.
-

Eli Lilly Strikes $475 M Gene Therapy Deal with MeiraGTx for Rare Retinal Disease
Eli Lilly’s $475 million acquisition of MeiraGTx marks a bold step into next-generation gene therapies targeting rare retinal diseases. Despite challenges in the gene therapy market, the move reflects growing optimism about using advanced genetic tools to improve the lives of patients with rare inherited disorders.


